To seek further insight into the activation mechanism of G-1749, we tested this molecule and G-9807 in cancer cell lines that we previously characterized for IRE1 pathway activity, i.e., KMS-11 multiple myeloma cells31, MDA-MB-231 triple-negative breast cancer cells (Fig. 6). The gene discussed is ERN1; the disease is plasma cell myeloma.